Federal contract award
2031ZA24F00604
LUXOR II TASK ORDER 9 AWARD.
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of the Treasury |
| Office | OFFICE OF THE CHIEF PROCUREMENT OFFICER |
| NAICS | 541715 — Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) |
| PSC | AJ13 — GENERAL SCIENCE & TECHNOLOGY R&D SVCS; GENERAL SCIENCE & TECHNOLOGY; EXPERIMENTAL DEVELOPMENT |
| Parent award / vehicle | 2031ZA21D00027 |
| Set-aside | Not reported |
| Pricing type | FIRM FIXED PRICE |
| Obligations | $3.2M |
| Current contract value | $3.2M |
| Potential contract value / ceiling | $3.2M |
| Start date | Sep 30, 2024 |
| Current end date | Apr 30, 2026 |
| Potential end date | Apr 30, 2026 |
| Latest award activity | Oct 15, 2025 |
| Source loaded | Sep 26, 2026 |
Funding and modification history
Showing the latest 4 of 4 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Oct 15, 2025 | P00003 | $0 | THE PURPOSE OF THIS NO-COST MODIFICATION FOR LUXOR II, TASK ORDER 09 (P00003), IS TO EXTEND THE PERIOD OF PERFORMANCE ENDING DATE FROM 10/30/2025 TO 4/30/26, BY THE AUTHORITY OF FAR 52.217-8, OPTION TO EXTEND SERVICES. |
| Sep 17, 2024 | 0 | $1.4M | LUXOR II TASK ORDER 9 AWARD. |
| Sep 17, 2024 | P00001 | $0 | THIS NO-COST MODIFICATION IS TO EXTEND BASE CLINS 0001 AND 0002 FROM MARCH 01, 2025, TO MAY 01, 2025, AND CHANGE THE PERIOD OF PERFORMANCE OF CLINS 0003 AND 0004 FROM MARCH 02, 2025, THROUGH NOVEMBER 30, 2025. |
| Sep 17, 2024 | P00002 | $1.8M | CHANGE THE BASE END DATES FOR CLINS 0001 AND 0002 FROM 05-01-2025 TO 04-01-2025, PERIOD OF PERFORMANCE DATES FOR CLINS 0003 AND 0004 FROM 05-02-2025 - 11-30-2025 TO 04-02-2025 THROUGH 10-30-2025, AND EXERCISE OPTION CLIN LINES 0003 AND 0004. |
Research next steps
- Confirm the ordering vehicle and your eligibility or a qualified teaming route.
- Review the award scope and buyer evidence before making a bid/no-bid decision.